Asensus Surgical, Inc.
New York Stock Exchange ArcaRecent
price
P/E
ratio
div
yld
- -
ROIC.AI
Capital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.- Similar Companies
- Business
- Asensus Surgical, Inc. (ASXC) develops and commercializes digital robotic surgery systems that digitize the surgeon-patient interface to enable performance-guided surgery and enhance minimally invasive procedures; its core offerings include the Senhance Surgical System, a multi-port robotic platform with up to four arms for controlling instruments and cameras in laparoscopic surgeries, complemented by 3mm and 5mm instruments including hooks, articulating devices, and the Senhance ultrasonic energy system for tissue ligation and division; additional products encompass the Intelligent Surgical Unit for real-time data integration and augmented intelligence features such as eye-tracking and force feedback. Founded in 2006 and headquartered in Durham, North Carolina, the company targets surgeons and hospitals in the United States, Europe, the Middle East, Africa, and Asia within the medical devices sector. In August 2024, Asensus Surgical completed its acquisition by KARL STORZ Endoscopy-America, Inc., a subsidiary of KARL STORZ SE & Co. KG, in a transaction valued at approximately $300 million, transitioning to operate as a subsidiary while accelerating development of the next-generation LUNA Surgical System, which promises improved robotic precision, dexterity, and integration with KARL STORZ's endoscopy portfolio; the company, formerly known as TransEnterix, Inc., rebranded to Asensus Surgical in February 2021 to reflect its focus on digital laparoscopy advancements.
Asensus Surgical Announces Closing of Acquisition by KARL STORZ
Asensus Surgical (ASXC) Reports Q2 Loss, Tops Revenue Estimates
Asensus Surgical, Inc. (ASXC) Q2 2024 Earnings Call Transcript
Asensus Surgical, Inc. Schedules Second Quarter Financial and Operating Results Conference Call for August 13, 2024
Asensus Surgical 2024 Special Meeting of Stockholders Is Adjourned
Independent Proxy Advisory Firm ISS Recommends Asensus Surgical Stockholders Vote “FOR” the Pending Merger with KARL STORZ
Glass Lewis Recommends Asensus Surgical Stockholders Vote “FOR” Proposals Relating to Proposed Merger with KARL STORZ
Asensus Surgical Receives FDA 510(k) Clearance for Senhance Surgical System in Urology
Asensus Surgical Announces LKH-Universitätsklinikum Graz Hospital in Austria to Initiate Senhance Surgery Program
Asensus Surgical (ASXC) Announces New Hospital Tie-Up on Senhance
Asensus Surgical Announces St. Marianna University School of Medicine Yokohama City Seibu Hospital in Japan to Initiate Senhance Surgery Program
Asensus Surgical (ASXC) Inks a Merger Agreement With KARL STORZ
SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates SQSP, ASXC on Behalf of Shareholders
ASENSUS SURGICAL INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Asensus Surgical, Inc. - ASXC
SHAREHOLDER ALERT: The M&A Class Action Investigates the Merger of Asensus Surgical, Inc. - ASXC
Shareholder Alert: Ademi LLP investigates whether Asensus Surgical, Inc. has obtained a Fair Price for its Public Shareholders
ASXC STOCK ALERT: Halper Sadeh LLC Is Investigating Whether the Sale of Asensus Surgical, Inc. Is Fair to Shareholders
Asensus Surgical Announces Signing of Definitive Merger Agreement with KARL STORZ
Asensus Surgical, Inc. (ASXC) Q1 2024 Earnings Call Transcript
Asensus Surgical (ASXC) Reports Q1 Loss, Tops Revenue Estimates